Streetbeat News

ICCM

IceCure Medical Ltd

https://www.icecure-medical.com

Industry

Medical - Devices

IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Open

1.38

Mkt cap

80M

Volume

166K

High

1.44

P/E Ratio

-5.07

52-wk high

1.66

Low

1.38

Div yield

N/A

52-wk low

0.48

An independent study in Japan showed 0% breast cancer local recurrence 5 years after treatment with IceCure's ProSense, demonstrating its potential as a standard treatment for early-stage breast cancer. The study, published in Breast Cancer journal, highlighted excellent cosmetic outcomes, high patient satisfaction, and improved quality of life post-cryoablation. IceCure's distribution partner in Japan, Terumo Corporation, plans to submit a regulatory clearance application for ProSense in H2 2024. IceCure expects to receive a total of $13.2 million from Terumo for exclusive distribution rights in Japan.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 12:45 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Icecure Medical (NASDAQ:ICCM) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

April 16, 2024 | 3:03 pm

IceCure Medical announced the final results of its ICE3 breast cancer cryoablation trial, submitting data to the FDA for marketing authorization to treat early-stage breast cancer. The data, presented at the ASBrS Annual Meeting and awarded the Scientific Impact Award, supports the use of cryoablation for early stage T1 invasive breast cancer with adjuvant hormone therapy. The company anticipates enhanced usage upon approval, citing the availability of a reimbursement code for facility expenses and the cost-effectiveness of its ProSense® cryoablation system.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:37 pm

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Icecure Medical (NASDAQ:ICCM) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 10:32 am

Icecure Medical (NASDAQ:ICCM) reported Q4 earnings with EPS of $(0.07), meeting analyst estimates, and sales of $1.25M, exceeding the $1.17M estimate by 7.26%.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 3:27 am

As of March 31, 2024, IceCure Medical (ICCM) reported having around $11M in cash and cash equivalents. The company has initiated an expense reduction plan to decrease its monthly cash usage, aiming to achieve its primary goals for 2024.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:36 pm

Icecure Medical (NASDAQ:ICCM) reported a FY EPS of $(0.32), meeting analyst consensus estimates and marking a 30.43% improvement over last year's $(0.46) per share. Quarterly sales reached $3.23M, exceeding the $3.14M estimate by 2.83% and showing a 4.67% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:33 pm

Earnings reports for April 3, 2024, include a mix of projected profits and losses across various sectors. Notable companies like Acuity Brands, Levi Strauss, and BlackBerry are among those reporting, with expectations ranging from significant earnings to losses per share.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 9:36 am

IceCure Medical has submitted a 510(k) application to the FDA seeking clearance for its XSense Cryoablation System, which includes cryoprobes. This step is crucial for the company as it aims to expand its product offerings in the medical device market, specifically in treatments that involve cryoablation technology.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 12:35 pm

Alliance Global Partners analyst Ben Haynor has maintained a Buy rating on Icecure Medical (NASDAQ:ICCM) and increased the price target from $1.9 to $2.9. This adjustment reflects a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 4:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.